Kiniksa Reports First Quarter 2021 Financial Results and Recent Corporate and Portfolio Activity
- ARCALYST® (rilonacept) launched as the first and only FDA-approved therapy for recurrent pericarditis - - Mavrilimumab Phase 2 severe COVID-19 data demonstrated a reduction in mechanical ventilation and death at Day 29; Phase 3 enrollment ongoing - - …